Susvimo
These highlights do not include all the information needed to use SUSVIMO safely and effectively. See full prescribing information for SUSVIMO. SUSVIMO™ (ranibizumab injection) for intravitreal use via SUSVIMO ocular implant Initial U.S. Approval: 2006
Approved
Approval ID
9c6d9e2a-9a77-4d11-b692-de87cfde3444
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Nov 17, 2022
Manufacturers
FDA
Genentech, Inc.
DUNS: 080129000
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Ranibizumab
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code50242-078
Application NumberBLA761197
Product Classification
M
Marketing Category
C73585
G
Generic Name
Ranibizumab
Product Specifications
Route of AdministrationINTRAVITREAL
Effective DateNovember 17, 2022
FDA Product Classification
INGREDIENTS (5)
HISTIDINEInactive
Code: 4QD397987E
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SUCROSEInactive
Code: C151H8M554
Classification: IACT
POLYSORBATE 20Inactive
Code: 7T1F30V5YH
Classification: IACT
RANIBIZUMABActive
Quantity: 100 mg in 1 mL
Code: ZL1R02VT79
Classification: ACTIB